YTHDF1, along with YTHDF2 and YTHDF3, redundantly suppresses the IFN‐γ response by destabilizing IRF1 mRNA, suggesting that these proteins can serve as viable therapeutic targets in cancer immunotherapy. The gene discussed is YTHDF1; the disease is cancer.